SCHEMBL7659637

SCHEMBL7659637

CC1(C)Oc2ccccc2CC1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 1/20 0.45
HPGD P15428 1/20 0.45
MAOA P21397 2/20 0.43
MAOB P27338 1/20 0.43
CYP1A2 P05177 1/20 0.37
AHR P35869 1/20 0.34
PDK2 Q15119 1/20 0.34
TP53 P04637 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
POLB P06746 1/20 0.33
LMNA P02545 1/20 0.33
HTR2A P28223 1/20 0.32
TDP2 O95551 1/20 0.32
CASP3 P42574 1/20 0.32
CASP7 P55210 1/20 0.32
CASP9 P55211 1/20 0.32
CASP6 P55212 1/20 0.32
CASP8 Q14790 1/20 0.32
MAP3K14 Q99558 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28744455 0.80 MAOA (0.39) ALDH1A1MAOAMAOBCYP1A2AHR
SCHEMBL9692443 0.75 KDM4E (0.44) ALDH1A1KDM4EHPGD
SCHEMBL11256569 0.74 MAOA (0.41) ALDH1A1MAOAMAOBCYP1A2AHR
SCHEMBL1115175 0.73 ALDH1A1 (0.41) ALDH1A1MAOAMAOBCYP1A2POLB
SCHEMBL21276097 0.73 SIGMAR1 (0.47) HTR2A
SCHEMBL6561118 0.72 KDM4E (0.41) ALDH1A1KDM4EHPGDAVPR1A
SCHEMBL28830167 0.72 MAPT (0.47) ALDH1A1KDM4EHPGDL3MBTL1POLB
SCHEMBL2120401 0.72 SMN1; SMN2 (0.35) ALDH1A1MAOAMAOBCYP1A2L3MBTL1
SCHEMBL8645380 0.72 KDM4E (0.41) ALDH1A1KDM4EHPGDCYP1A2POLB
SCHEMBL8794691 0.72 TDP2 (0.46) ALDH1A1KDM4EHPGDLMNATDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-8310981-A None JP disclosed
US-11649242-B2 Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators FORMA THERAPEUTICS, INC. (US) 2023-05-16 US disclosed
EP-2871187-B1 NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT SNU R&DB FOUNDATION (KR) 2017-09-20 EP disclosed
US-9745280-B2 Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient SNU R&DB FOUNDATION (KR) 2017-08-29 US disclosed
US-20160340331-A1 NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT SNU R&DB FOUNDATION (KR) 2016-11-24 US disclosed
US-20150183797-A1 NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT SNU R&DB FOUNDATION (KR) 2015-07-02 US disclosed
EP-2871187-A1 NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT SNU R&DB Foundation (KR) 2015-05-13 EP disclosed
CN-101843908-B Contrast agents for myocardial perfusion imaging BRISTOL MYERS SQUIBB PHARMA CO 2014-09-10 CN disclosed
US-8791111-B2 Piperidine and piperazine derivatives MERCK PATENT GMBH (DE) 2014-07-29 US disclosed
US-8754097-B2 Piperidine and piperazine derivatives MERCK PATENT GMBH (DE) 2014-06-17 US disclosed
US-20100222341-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HARTUNG (DE) 2010-09-02 US disclosed
CN-1976728-A Contrast agents for myocardial perfusion imaging BRISTOL MYERS SQUIBB PHARMA CO (US) 2007-06-06 CN disclosed
WO-2002005830-A2 EXTRACTS FROM CRASSULACEAN ACID METABOLISM (CAM) MECHANISM PLANTS AND USES THEREOF KANE SHANTARAM GOVIND (IN) 2002-01-24 WO disclosed
US-5756790-A FROM KETONES MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1998-05-26 US disclosed
JP-H08310981-A PRODUCTION OF OPTICALLY ACTIVE ALCOHOL MITSUI PETROCHEM IND LTD 1996-11-26 JP disclosed
EP-0298452-B1 2H-1-BENZOPYRANE DERIVATIVES SUBSTITUTED IN POSITION 4 BY ARYL OR N-HETEROARYL F. HOFFMANN-LA ROCHE AG (CH) 1993-06-30 EP disclosed
US-5112855-A Nootropic Agents CIBA-GEIGY CORPORATION (US) 1992-05-12 US disclosed
US-4957928-A NOOTROPIC AGENTS, COGNITION ACTIVATORS CIBA-GEIGY CORPORATION (US) 1990-09-18 US disclosed
EP-0322361-A2 Hydrogenated 1-benzooxacycloalkyl pyridine-carboxylic-acid compounds CIBA-GEIGY AG (CH) 1989-06-28 EP disclosed
EP-0298452-A2 2H-1-benzopyrane derivatives substituted in position 4 by aryl or N-heteroaryl F. HOFFMANN-LA ROCHE AG (CH) 1989-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150183797-A1 NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT HSP90AB1, HSP90AA1, HIF1AN ALDH1A1 355/4885KDM4E 2649/4885HPGD 905/4885
US-20100222341-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES CCND2, CCND1, TPD52L2 ALDH1A1 389/4885KDM4E 1517/4885HPGD 195/4885
US-11649242-B2 Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators PDK1, PKM, PKLR ALDH1A1 3741/4885KDM4E 1231/4885HPGD 1603/4885
US-20160340331-A1 NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT HSP90AB1, HSP90AA1, HSP90AB2P ALDH1A1 963/4885KDM4E 2949/4885HPGD 1314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.